Arcadia hopes health care reform means more revenue
The CEO of Indianapolis-based Arcadia Resources said the environment is perfect for his company’s fast-growing DailyMed
service.
Pharmaceutical
Articles
Lilly’s Effient launch just one of its many challenges
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
Lilly cancels trials for experimental MS drug
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Professors go online to revolutionize drug discovery
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
Drug industry funds Democrat-led panel on health care reform
The pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
Potential obesity breakthrough boosts Marcadia
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
BREAKING: FDA approves Lilly blood-thinner prasugrel
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
Lilly asks FDA to review weekly diabetes drug
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Lilly cancer drug OK’d for new use
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
Profs trying to revolutionize drug discovery process
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
With Byetta’s sales stalled, Lilly unveils its own competitor
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
Biotechnology firm boosts its protein biz
Greenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on protein
business.
With pharma famine looming, Lilly relying on snack-size deals
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individuals
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
In spite of criticism, Lilly saves lives
My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local doctors.
Logistics firm grows
MD Logistics has completed a coldstorage facility for pharmaceutical products in its hometown of Plainfield.
Biotech push may help offset generic competition; some analysts skeptical
Lilly executives want to make biotech their top focus.
Lilly makes $6.5B acquisition
Eli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim
Cornelius—and won.
Generic meds cost more than consumers realize
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
Lilly fighting with generic drug firms over Cymbalta, Alimta, 5 other medications
Eli Lilly & Co. has filed lawsuits against seven generic drug companies in federal court in Indianapolis, asking a judge to
declare its Cymbalta patent valid and to tell the generic companies to back off.